SynBioBeta Speaker
Sushmita Sudarshan
Molecular Devices
Application Scientist, Assay Dev.
Dr. Sushmita Sudarshan is the Applications Scientist of Assay Development at Molecular Devices. With a Ph.D. in Molecular Biology from the University of Texas at Dallas, she brings over a decade of expertise in microbial research, assay development, and lab automation. Her work spans academic and industry settings, including roles at Isolation Bio and Molecular Devices, where she advances bioanalytical instrumentation and supports automation in microbial and mammalian workflows. Dr. Sudarshan specializes in integrating and validating complex assays, driving product innovation, and collaborating with scientists to accelerate discovery through optimized, high-throughput solutions.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Sushmita
This Year
•
-
Tools & Tech
The Democratization of Scale: From Billion-Dollar Facilities to Desktop Biology
For decades, meaningful progress in biotechnology depended on access to million to billion-dollar facilities, specialized infrastructure, and industrial-scale equipment. Today, that paradigm is rapidly shifting. A new generation of tools, from smart shake flasks and modular bioreactors to microfluidic platforms, desktop DNA printers, and compact sequencing devices; is compressing the scale of biological experimentation while expanding who can participate. These technologies are transforming the economics of innovation, enabling startups, academic labs, and distributed research teams to design, build, and test biological systems without massive capital investment. As instrumentation becomes smaller, smarter, and increasingly automated, biology is moving from centralized mega-facilities toward a more distributed model of experimentation. This session explores how advances in lab automation, miniaturized bioreactors, and accessible bioinstrumentation are lowering the barriers to experimentation — and what this shift means for the speed, diversity, and geography of the next wave of bioinnovation.
•
-
Tools & Tech
The Democratization of Scale: From Billion-Dollar Facilities to Desktop Biology
For decades, meaningful progress in biotechnology depended on access to million to billion-dollar facilities, specialized infrastructure, and industrial-scale equipment. Today, that paradigm is rapidly shifting. A new generation of tools, from smart shake flasks and modular bioreactors to microfluidic platforms, desktop DNA printers, and compact sequencing devices; is compressing the scale of biological experimentation while expanding who can participate. These technologies are transforming the economics of innovation, enabling startups, academic labs, and distributed research teams to design, build, and test biological systems without massive capital investment. As instrumentation becomes smaller, smarter, and increasingly automated, biology is moving from centralized mega-facilities toward a more distributed model of experimentation. This session explores how advances in lab automation, miniaturized bioreactors, and accessible bioinstrumentation are lowering the barriers to experimentation — and what this shift means for the speed, diversity, and geography of the next wave of bioinnovation.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
